

Corp. Office : 1st to 4th Floor, SM House, 11, Sahakar Road, Vile Parle (East), Mumbai - 400 057.
Tel. : (91-22) 6726 1000 Fax : (91-22) 6726 1068 E-mail : info@guficbio.com, CIN No. L24100MH1984PLC033519

157/LG/SE/JULY/2019/GBSL

July 26, 2019

To,
Listing Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Security Code : 509079

To,
Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Security Code : GUFICBIO

Dear Sir,

Sub.: Submission of Report on Reconciliation of Share Capital Audit for the quarter ended June 30, 2019.

With reference to above, we submit herewith Report on Reconciliation of Share Capital Audit for the quarter ended June 30, 2019 for reconciliation of share capital in electronic mode and physical mode, received from M/s. Gajanan D. Athavale, Practicing Company Secretary, Mumbai.

Kindly take the same on record.

Thanking you,

Yours faithfully,

For Gufic Biosciences Limited

AMI SHAH

Ami N. Shah
Company Secretary & Compliance Officer
Mem No. A39579

Encl: A/a





To,
The Board of Directors,
Gufic Biosciences Limited.
Mumbai

Reconciliation of Share Capital Audit of M/s. Gufic Biosciences Limited
BSE Scrip Code: 509079
NSE Scrip Code: GUFICBIO
Company Identification Number: L65990MH1984PLC033519

Sir/Madam,

Based on reports of the Company appointed Registrars and Transfer Agents; M/s. Link Intime India Pvt. Ltd. dated 03 July 2019, which was further supported by the management's written representation dated 24 July 2019; in terms of Regulation 55A of the SEBI (Depositories and Participants) Regulations, 1996 read with the Circular D&CC/FITTC/CIR-16/2002 dated 31 December 2002 as amended by the Circular No. SEBI/MRD/ Policy/Cir-13/2004 dated March 3, 2004 and circular CIR/MRD/DP/30/2010 dated 06 September 2010, *presently in force and to the extent superseded by Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018*; I hereby report on the reconciliation of share capital of Gufic Biosciences Limited for the quarter ended 30 June 2019 as follows in a prescribed format:

Sr. No.	Particulars		
1.	For the quarter ended	30 June 2019	
2.	ISIN	INE742B01025	
3.	Face Value	Re.1/-	
4.	Name of the Company	Gufic Biosciences Limited	
5.	Registered Office Address	Shop 37, First Floor, Kamala Bhavan II, S Nityanand Road, Andheri (East), Mumbai – 400 069	
6.	Correspondence Address (Corporate Office)	SM house, 11 Sahakar Road, Vile Parle (East), Mumbai – 400057	
7.	Telephone & Fax	Tele: 022 – 67261000 Fax: 022 – 67261067	
8.	Email ID	mgr_legal@guficbio.com	
9.	Names of the Stock Exchanges where the company's securities are listed	1. Bombay Stock Exchange Limited (BSE) 2. National Stock Exchange of India Limited (NSE)	
10.	Issued Capital	Number of Equity Shares	issued capital %
		77,830,000	100
11.	Listed Capital (Exchange-wise) (as per company records)	77,830,000 (similar listing on both exchanges viz: BSE & NSE)	100
12.	Held in dematerialised form in NSDL	72,510,442	93.17
13.	Held in dematerialised form in CDSL	5,196,062	6.68
14.	Physical	123,496	0.15
15.	Total No. of Shares (12 + 13 + 14)	77,830,000	100.00
16.	Reasons for difference if any, between (10 & 11), (10 & 15), (11 & 15)	--- N.A. ---	





17.	Certifying the details of changes in share capital during the quarter under consideration as per table below:						
	Particulars (Rights, Bonus, Preferential Issue, ESOPs, Amalgamation, Conversion, Buyback, Capital Reduction, Forfeiture, any other (to specify))	No. of shares	Applied / Not Applied for listing	Listed on Stock Exchanges (Specify Names)	Whet her intima ted to CDSL	Whet her intima ted to NSDL	In principle approval pending for SE (Specify names)
----- N.A. -----							
18.	Register of Members is updated (Yes / No) If not, updated upto which date				Yes (as confirmed by RTA vide its letter dated 03 July 2019.)		
19.	Reference of previous quarter with regards to excess dematerialised shares, if any.				N.A.		
20.	Has the company resolved the matter mentioned in point no.19 above in the current quarter? If not, reason why?				N.A.		
21.	Mentioned the total no. of requests, if any, confirmed after 21 days and the total no. of requests pending, beyond 21 days with the reasons for delay.						
	Total no. of demat requests		No. of requests	No. of shares	Reasons for delay		
	Confirmed after 21 days		As per RTA report generated on 03 July 2019, <i>DEMAT requests were received and released within time framed as per SEBI letter reference no. MRD/DOP2/DSA2/OW/2019/2498/1 & MRD/DOP2/DSA2/OW/2019/2503/1 dated January 24, 2019.</i>				
Pending for more than 21 days							
22.	Name, Telephone & Fax No. of the Compliance Officer of the Company		Ami Shah, Company Secretary & Compliance Officer Tel: 022 – 67261000 Fax: 022 – 67261067				
23.	Name, Address, Tel. & Fax No., Regn. no. of the Auditor		Gajanan D. Athavale, Company Secretaries 24, Minerva Mansion, Dr. Ambedkar Road, Dadar (East), Mumbai, Maharashtra State – 400 014 Membership No. F-9177 CoP No. 10121				
24.	Appointment of common agency for share registry work, if yes (name & address)		LINK INTIME INDIA PVT. LTD. C-101, 247 Park, L.B.S. Marg, Vikhroli (W), Mumbai - 400 083. Tel No.: (022) 4918 6270 Fax (022) 49186060 Email: rnt.helpdesk@linkintime.co.in				
25.	Any other detail that the auditor may like to provide. (e.g. BIFR company, delisting from SE, company changed its name etc.)		N.A.				

For Gajanan D. Athavale
Company Secretaries



Gajanan D. Athavale
Proprietor

Membership No. FCS-9177 | Certificate of Practice: 10121

Place: Mumbai | Date: 24 July 2019